Latest Security News

BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.

Aurora Labs reported a 34% increase in loss after tax to $3.75 million for FY2025, alongside a 327% surge in revenue driven by defence contracts and 3D printing services. The company is progressing its micro gas turbine propulsion systems and pursuing aerospace certification to expand its market footprint.

BNK Banking Corporation Limited has reported a significant turnaround in its FY25 financial results, driven by margin expansion and a robust capital position. The bank’s strategic portfolio reshaping and disciplined cost management underpin its improved profitability and outlook.

BTC Health reports a strong FY25 with a $4 million statutory profit, boosted by a $5 million contract and strategic acquisition. The company eyes further growth in FY26 with new product launches and expanded market reach.

BTC Health Limited reported a remarkable 277% increase in profit after tax to nearly $4 million for FY25, driven by significant fair value gains on its healthcare investments and key contract wins.

NEXTDC’s FY25 results reveal robust financial growth driven by surging AI and cloud demand, alongside a strategic joint venture to expand its Western Sydney data centre footprint.

NEXTDC has delivered record FY25 financial results, surpassing revenue and EBITDA guidance while aggressively expanding its data centre footprint across Australia and Asia-Pacific. The company’s strengthened liquidity and strategic investments position it to capitalise on soaring AI and cloud demand.

NEXTDC Limited reported a 6% rise in FY25 revenue and underlying EBITDA, offset by a widened loss due to a $2.9 billion debt refinancing. The company’s strategic expansion in AI-ready data centres and a strengthened $6.4 billion debt facility position it for significant growth.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

Brazilian Critical Minerals Ltd has converted a significant portion of its outstanding debt into equity, issuing over 120 million shares to a key investor, while also raising a modest $50,000 through a new share placement to support working capital.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.